3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
News and updates
All
3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of Navarra
Viral safety in viral vector applications – what you need to know?
3P Biopharmaceuticals makes a significant donation to help Ukraine
Dámaso Molero, appointed member of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.
ANLBIO selected Biovian for manufacturing of AAV-based product for the treatment of Alzheimer’s disease.
Support functions at Biovian – warehousing, purchasing, and sterile supply management.
Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE
3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA
3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology
3P Biopharmaceuticals receives FDA approval
How to select a CDMO for a biopharmaceutical project or program.
Lokon Pharma AB signs an agreement with Biovian
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a cGMP manufacturing collaboration to develop a new treatment to combat solid tumours
Viral Vector and gene therapy basics summarized
Working in biotechnology means working to improve the planet and people’s lives
